[HTML][HTML] New insights about albumin and liver disease
JR Carvalho, MV Machado - Annals of hepatology, 2018 - Elsevier
Decompensated liver cirrhosis has a dismal prognosis, with an overall survival of 2-4 years,
which is worse than for many oncological diseases. Albumin is an important tool in the …
which is worse than for many oncological diseases. Albumin is an important tool in the …
AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: expert review
Description Cirrhosis is a major cause of morbidity and mortality in the United States and
worldwide. It consists of compensated, decompensated, and further decompensated stages; …
worldwide. It consists of compensated, decompensated, and further decompensated stages; …
Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: neurology, peri-transplant medicine, infectious disease, and …
R Nanchal, R Subramanian, W Alhazzani… - Critical care …, 2023 - journals.lww.com
OBJECTIVES: To develop evidence-based recommendations for clinicians caring for adults
with acute liver failure (ALF) or acute on chronic liver failure (ACLF) in the ICU. DESIGN: The …
with acute liver failure (ALF) or acute on chronic liver failure (ACLF) in the ICU. DESIGN: The …
Albumin administration is efficacious in the management of patients with cirrhosis: a systematic review of the literature
G Zaccherini, M Tufoni, M Bernardi - Hepatic Medicine: Evidence …, 2020 - Taylor & Francis
The use of albumin in patients with cirrhosis has been extensively discussed over recent
years. Current treatment approaches depend on targeting related complications, aiming to …
years. Current treatment approaches depend on targeting related complications, aiming to …
Meta‐analysis: efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis
L Leache, M Gutiérrez‐Valencia… - Alimentary …, 2023 - Wiley Online Library
Introduction Albumin is used in multiple situations in patients with cirrhosis, but the evidence
of its benefit is not always clear. The aim was to synthesise the evidence on the efficacy and …
of its benefit is not always clear. The aim was to synthesise the evidence on the efficacy and …
[HTML][HTML] Efficacy of intravenous albumin for spontaneous bacterial peritonitis infection among patients with cirrhosis: a meta-analysis of randomized control trials
S Batool, MD Waheed, K Vuthaluru, T Jaffar… - Cureus, 2022 - ncbi.nlm.nih.gov
Albumin is an important component in the standard therapeutic approach to spontaneous
bacterial peritonitis (SBP). This meta-analysis aimed to determine the impact of intravenous …
bacterial peritonitis (SBP). This meta-analysis aimed to determine the impact of intravenous …
Practice guidance for the use of terlipressin for liver cirrhosis–related complications
X Qi, Z Bai, Q Zhu, G Cheng, Y Chen… - Therapeutic …, 2022 - journals.sagepub.com
Background: Liver cirrhosis is a major global health burden worldwide due to its high risk of
morbidity and mortality. Role of terlipressin for the management of liver cirrhosis–related …
morbidity and mortality. Role of terlipressin for the management of liver cirrhosis–related …
[PDF][PDF] 16 层螺旋CT 灌注成像对肝硬化血流状态的评估及与肝硬化程度的相关性研究
刘美兰， 杜兆峰， 薄健， 马强， 梁明… - 现代生物医学 …, 2018 - biomed.cnjournals.com
摘要目的: 探讨16 层螺旋CT 灌注成像对肝硬化血流状态的评估价值及其与肝硬化程度的相关性
. 方法: 选取2014 年1 月至2016 年1 月于我院接受诊治的肝硬化患者126 例作为肝硬化组 …
. 方法: 选取2014 年1 月至2016 年1 月于我院接受诊治的肝硬化患者126 例作为肝硬化组 …
特利加压素在肝硬化并发症临床应用的实践指导(2021 版).
谢渭芬， 郭晓钟， 杨永平… - Journal of Clinical …, 2022 - search.ebscohost.com
肝硬化患病人数多, 死亡风险高, 是全球疾病负担的重要组成部分之一. 近年来,
特利加压素在肝硬化相关并发症中的作用已逐渐得到认可. 中华医学会消化病学分会肝胆疾病学 …
特利加压素在肝硬化相关并发症中的作用已逐渐得到认可. 中华医学会消化病学分会肝胆疾病学 …
特利加压素治疗失代偿期乙型肝炎肝硬化患者消退腹水的作用及对肝肾功能的影响
程亚， 乔晓斐， 荚卫东 - 实用肝脏病杂志, 2016 - manu43.magtech.com.cn
目的探讨特利加压素对失代偿期乙型肝炎肝硬化患者肝肾功能的影响及对腹水的治疗作用.
方法回顾性分析2014 年8 月至2016 年4 月安徽省立医院肝脏外科收治的50 …
方法回顾性分析2014 年8 月至2016 年4 月安徽省立医院肝脏外科收治的50 …